Novellia Launches AI-Powered, Cross-Industry Research Initiative to Transform Breast Cancer Care
First-of-its-kind quality improvement initiative, Project EVEREST, is backed by Daiichi Sankyo, Genentech, and AstraZeneca.
NEW YORK, May 28, 2025 – Novellia, Inc., the AI health data platform trusted by leading biopharma companies to uncover hidden insights in real-world patient data, today announced the launch of Project EVEREST—a groundbreaking, cross-industry initiative designed to improve adherence to clinical guidelines in the treatment of early and metastatic breast cancer. Project EVEREST unites leading researchers, clinicians, and biopharmaceutical companies—including Daiichi Sankyo, Genentech, and AstraZeneca—to identify and address the barriers preventing consistent, evidence-based cancer care across health care settings.
As the first AI-enabled, patient-permissioned longitudinal registry focused on real-world treatment adherence in breast cancer, Project EVEREST brings together a cross-industry coalition to set a new standard for quality improvement research.
Leveraging Novellia’s proprietary AI platform, Project EVEREST will create a robust, longitudinal patient registry by unifying complex medical histories across NCI-designated cancer centers, lab centers, and regional health systems. Researchers from the University of Alabama at Birmingham (UAB) will analyze these unified datasets to uncover patterns in care delivery, identify actionable gaps in the application of current breast cancer treatment guidelines, and deliver targeted recommendations for improving treatment consistency and patient outcomes.
“The key question we aim to answer is what systemic and clinical factors are preventing patients from receiving the most current, evidence-based care for breast cancer,” said Dr. Humaira Sarfraz, Assistant Professor of Medicine and clinician-educator in the Division of Hematology and Oncology at the UAB Medical Center. “The field of oncology is moving at an unprecedented rate, and next-generation, AI-enabled data platforms open up possibilities for us to drive better outcomes for patients by examining real-world data along with patient medical histories and pinpoint where care may fall short in ways that were previously impossible or time prohibitive.”
“When biopharma teams face questions others can’t answer, they turn to Novellia for our unique ability to build full, sequential patient stories that reveal hidden insights traditional data providers aren’t equipped to find. Project EVEREST builds on our reputation as the only data partner that goes deep enough to solve the toughest challenges in healthcare.,” said Shashi Shankar, CEO and co-founder of Novellia. “In the past, building these sorts of longitudinal datasets would have cost tens of millions of dollars and required several months of manual data processing by teams of clinical abstractors. By using AI to autonomously unify fragmented health histories and surface critical blind spots missed by traditional real-world data solutions, we’re closing the gap between data and decisions. Project EVEREST brings together biopharma leaders, top researchers, and our AI-enabled platform to deliver a scalable model for evidence-based care improvement in breast cancer—and a roadmap for addressing care variation across other complex diseases.”
The program will enroll early and metastatic breast cancer patients, including those with HER2+ and HR+/HER2- subtypes. Over a 24-month period, researchers will aggregate and analyze hundreds of thousands of retrospective and prospective patient records to identify trends and deviations from established treatment guidelines. In Phase 2, researchers will then deliver tailored, evidence-based interventions to support health systems and community oncologists in optimizing care delivery, advancing the standard of care through measurable, real-world impact and improved patient outcomes.
Previous clinical research has demonstrated that Novellia’s AI-enabled platform can uncover new insights that help improve clinical decision-making, patient outcomes, and the overall quality of care. The data has been featured at leading industry conferences, including the 2024 ASCO Quality Care Symposium and the 2024 San Antonio Breast Cancer Symposium. Learn more about IMPACT-NSCLC and Project EVOLVE.
About Novellia
Novellia is the AI-enabled data partner trusted by leading biopharma companies to uncover hidden insights in real-world patient data. Through proprietary AI and patient-permissioned data access, Novellia unifies fragmented records into full, sequential patient stories to surface critical trends and signals that traditional data providers miss.
Novellia’s patient-facing platform empowers individuals to become their own best advocate in their care journey by centralizing health records, enabling personalized, proactive care management, and offering the choice to contribute anonymized data to support medical research. This depth of insight helps biopharma close the gap between data and decisions to advance therapeutic development and enable more effective, patient-centered care.
Novellia was recently named “Best Electronic Health Record Service” in the 9th annual MedTech Breakthrough Awards program, recognizing its leadership and innovation in AI-powered health data. To learn more visit novellia.com.
